Sandoz Group Ltd ( (SDZXF) ) has released its Q2 earnings. Here is a breakdown of the information Sandoz Group Ltd presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sandoz Group Ltd is a leading global pharmaceutical company specializing in generic and biosimilar medicines, committed to improving patient access to affordable healthcare solutions. In the first half of 2025, Sandoz Group Ltd reported robust financial performance, with net sales reaching USD 5.2 billion, marking a 4% increase at constant currencies. The company’s core EBITDA margin improved to 20.0%, and core diluted earnings per share rose by 33% at constant currencies. Key highlights include the successful launch of several biosimilar products, such as Pyzchiva and Wyost, contributing to a strong 17% growth in the biosimilars segment. Sandoz also announced strategic expansions, including a new facility in Slovenia and the proposed acquisition of Just-Evotec Biologics EU SAS, to bolster its biosimilar capabilities. Looking ahead, Sandoz aims to maintain its growth momentum by capitalizing on the significant market opportunities in biosimilars and generics, while continuing to advocate for regulatory and pricing reforms to enhance global healthcare access.